Home » ALTANA TO LEAD ONCOLOGY PRODUCTS INTO PHASE I TRIALS
ALTANA TO LEAD ONCOLOGY PRODUCTS INTO PHASE I TRIALS
Altana has announced that it expects to lead its oncology projects into clinical Phase I trials in the next two years. In oncology, Altana focuses on the development of antimitotic cancer agents to substitute for current taxane-based chemotherapy.
The company also wants to bring the next generation of HDAC (histone deacetylase) inhibitors, which hems growth in a wide range of tumor models. The objective of this oncology research is to find compounds that will allow for longterm treatment to turn cancer into a chronic controlled disease.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May